Oral treatment with  improves insulin sensitivity in  mice

Shanthadevi Udayappan; Louise Manneras-Holm; Alice Chaplin-Scott; Clara Belzer; Hilde Herrema; Geesje M Dallinga-Thie; Silvia H Duncan; Erik S G Stroes; Albert K Groen; Harry J Flint; Fredrik Backhed; Willem M de Vos; Max Nieuwdorp

doi:10.1038/npjbiofilms.2016.9

Oral treatment with improves insulin sensitivity in mice

Shanthadevi Udayappan, Louise Manneras-Holm, Alice Chaplin-Scott, Clara Belzer, Hilde Herrema, Geesje M Dallinga-Thie, Silvia H Duncan, Erik S G Stroes, Albert K Groen, Harry J Flint, Fredrik Backhed, Willem M de Vos, Max Nieuwdorp

72 Citations (Scopus)

80 Downloads (Pure)

Abstract

An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.

Original language	English
Article number	16009
Journal	npj Biofilms and Microbiomes
Volume	2
Number of pages	10
ISSN	2055-5008
DOIs	https://doi.org/10.1038/npjbiofilms.2016.9
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/npjbiofilms.2016.9Licence: CC BY

Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db miceFinal published version, 1.2 MBLicence: CC BY

Cite this

@article{e71064337f114a0eafd44d3c17f3a2d3,

title = "Oral treatment with improves insulin sensitivity in mice",

abstract = "An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.",

author = "Shanthadevi Udayappan and Louise Manneras-Holm and Alice Chaplin-Scott and Clara Belzer and Hilde Herrema and Dallinga-Thie, {Geesje M} and Duncan, {Silvia H} and Stroes, {Erik S G} and Groen, {Albert K} and Flint, {Harry J} and Fredrik Backhed and {de Vos}, {Willem M} and Max Nieuwdorp",

year = "2016",

doi = "10.1038/npjbiofilms.2016.9",

language = "English",

volume = "2",

journal = "npj Biofilms and Microbiomes",

issn = "2055-5008",

publisher = "nature publishing group",

}

TY - JOUR

T1 - Oral treatment with improves insulin sensitivity in mice

AU - Udayappan, Shanthadevi

AU - Manneras-Holm, Louise

AU - Chaplin-Scott, Alice

AU - Belzer, Clara

AU - Herrema, Hilde

AU - Dallinga-Thie, Geesje M

AU - Duncan, Silvia H

AU - Stroes, Erik S G

AU - Groen, Albert K

AU - Flint, Harry J

AU - Backhed, Fredrik

AU - de Vos, Willem M

AU - Nieuwdorp, Max

PY - 2016

Y1 - 2016

N2 - An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.

AB - An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype.

U2 - 10.1038/npjbiofilms.2016.9

DO - 10.1038/npjbiofilms.2016.9

M3 - Journal article

C2 - 28721246

SN - 2055-5008

VL - 2

JO - npj Biofilms and Microbiomes

JF - npj Biofilms and Microbiomes

M1 - 16009

ER -

Oral treatment with improves insulin sensitivity in mice

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this